CLDX Celldex Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CLDX

Price (delayed)

$38.37

Market cap

$3.01B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.27

Enterprise value

$2.98B

?
Relative Growth: Rel. Growth: 2
Relative Strength: Rel. Strength: 83
Relative Valuation: Rel. Valuation: 1
Relative Profitability: Rel. Profitability: 25

Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which ...

Highlights
The debt has decreased by 44% YoY and by 18% QoQ
The company's gross profit has shrunk by 89% YoY and by 44% QoQ
Celldex Therapeutics's revenue has plunged by 89% YoY and by 44% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.celldex.com
Peers: AGEN EBS PFE NVAX

Key stats

What are the main financial stats of CLDX

CLDX stock price

How has the Celldex Therapeutics stock price performed over time
Intraday
4.32%
1 week
12.56%
1 month
32.77%
1 year
73.54%
YTD
41.27%
QTD
3.12%

Financial performance

How have Celldex Therapeutics's revenue and profit performed over time
Revenue
$866,000
Gross profit
$866,000
Operating income
-$309.06M
Net income
-$283.65M
Gross margin
100%
Net margin
-32,753.6%
The net margin has shrunk by 96% QoQ
CLDX's operating margin has dropped by 92% since the previous quarter
The company's gross profit has shrunk by 89% YoY and by 44% QoQ
Celldex Therapeutics's revenue has plunged by 89% YoY and by 44% from the previous quarter

Price vs fundamentals

How does CLDX's price correlate with its fundamentals

Growth

What is Celldex Therapeutics's growth rate over time

Valuation

What is Celldex Therapeutics stock price valuation
P/E
N/A
P/B
5.6
P/S
2,949.35
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3,438.71
CLDX's EPS has plunged by 58% YoY and by 9% from the previous quarter
The P/B is 75% higher than the last 4 quarters average of 3.2 and 44% higher than the 5-year quarterly average of 3.9
Celldex Therapeutics's equity has decreased by 35% YoY and by 13% from the previous quarter
CLDX's price to sales (P/S) is 162% higher than its last 4 quarters average of 1125.0
Celldex Therapeutics's revenue has plunged by 89% YoY and by 44% from the previous quarter

Efficiency

How efficient is Celldex Therapeutics business performance
Celldex Therapeutics's ROIC has plunged by 123% YoY and by 24% from the previous quarter
The ROE has plunged by 116% YoY and by 22% from the previous quarter
The ROA has shrunk by 108% YoY and by 20% QoQ
CLDX's ROS has plunged by 96% from the previous quarter

Dividends

What is CLDX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CLDX.

Financial health

How did Celldex Therapeutics financials performed over time
The current ratio has plunged by 59% YoY and by 15% from the previous quarter
CLDX's quick ratio has dropped by 58% year-on-year and by 14% since the previous quarter
The debt is 100% lower than the equity
The debt has decreased by 44% YoY and by 18% QoQ
Celldex Therapeutics's equity has decreased by 35% YoY and by 13% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.